MOUNTAIN VIEW, Calif. — It’s half past noon on a recent Tuesday at the Silicon Valley office of health-tech startup Livongo, and a U.S. map projected on a screen is flashing with pins that pop up and then disappear like fireworks. Each of the 5,000 pins marks the spot where a diabetes patient in Livongo’s program has just beamed in a new blood glucose reading. Most of the pins are green, meaning that the patient’s blood sugar is at a safe level, but some are blue, denoting a level too low, or red, for too high.

These days, Livongo is processing more than 100,000 such readings daily — a sign of the chronic disease-coaching company’s rapid growth ahead of an expected initial public offering sometime this year. It’s likely to be among the first of a new breed of health-tech startups to brave the public markets.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Your daily dose of news in health and medicine

Privacy Policy